Latest Insider Transactions at Nurix Therapeutics, Inc. (NRIX)
This section provides a real-time view of insider transactions for Nurix Therapeutics, Inc. (NRIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nurix Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nurix Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,760
-3.45%
|
$67,680
$18.21 P/Share
|
|
Dec 18
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,760
+6.44%
|
$3,760
$1.86 P/Share
|
|
Nov 24
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
37,600
-42.49%
|
$639,200
$17.07 P/Share
|
|
Nov 24
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,600
+29.82%
|
$37,600
$1.86 P/Share
|
|
Nov 03
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,284
-14.32%
|
$75,408
$12.56 P/Share
|
|
Oct 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,130
-6.66%
|
$37,560
$12.8 P/Share
|
|
Oct 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+6.32%
|
-
|
|
Oct 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,087
-5.06%
|
$49,044
$12.8 P/Share
|
|
Oct 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,815
+3.72%
|
-
|
|
Oct 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,644
-6.68%
|
$43,728
$12.8 P/Share
|
|
Oct 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,532
+4.94%
|
-
|
|
Sep 17
2025
|
Julia P Gregory Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,750
+50.0%
|
$10,750
$1.86 P/Share
|
|
Aug 01
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,402
-13.2%
|
$59,422
$11.03 P/Share
|
|
Jul 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,308
-5.87%
|
$51,696
$12.01 P/Share
|
|
Jul 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,815
+4.11%
|
-
|
|
Jul 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,841
-8.03%
|
$46,092
$12.01 P/Share
|
|
Jul 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,532
+5.66%
|
-
|
|
Jul 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,304
-9.52%
|
$51,648
$12.01 P/Share
|
|
Jul 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,494
+6.58%
|
-
|
|
May 02
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,198
-15.53%
|
$68,178
$11.33 P/Share
|
|
Apr 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,438
-5.76%
|
$26,818
$11.5 P/Share
|
|
Apr 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+6.79%
|
-
|
|
Apr 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,894
-7.2%
|
$31,834
$11.5 P/Share
|
|
Apr 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+6.34%
|
-
|
|
Apr 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,377
-5.2%
|
$37,147
$11.5 P/Share
|
|
Apr 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,956
+4.59%
|
-
|
|
Mar 03
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,825
-7.5%
|
$81,550
$14.77 P/Share
|
|
Jan 31
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-7.54%
|
$115,200
$20.21 P/Share
|
|
Jan 31
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+6.65%
|
$5,760
$1.86 P/Share
|
|
Jan 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,220
-4.54%
|
$64,400
$20.07 P/Share
|
|
Jan 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+7.13%
|
-
|
|
Jan 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,690
-3.11%
|
$73,800
$20.07 P/Share
|
|
Jan 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,957
+5.0%
|
-
|
|
Jan 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,811
-3.34%
|
$56,220
$20.07 P/Share
|
|
Jan 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+6.79%
|
-
|
|
Jan 02
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$109,440
$19.5 P/Share
|
|
Jan 02
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|
|
Dec 02
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$120,960
$21.73 P/Share
|
|
Dec 02
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|
|
Nov 04
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,290
-10.49%
|
$82,250
$25.0 P/Share
|
|
Nov 04
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,290
+9.49%
|
$29,610
$9.57 P/Share
|
|
Nov 01
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,546
-9.51%
|
$85,104
$24.28 P/Share
|
|
Nov 01
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$138,240
$24.28 P/Share
|
|
Nov 01
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|
|
Oct 30
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,182
-12.96%
|
$100,368
$24.3 P/Share
|
|
Oct 30
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+7.91%
|
-
|
|
Oct 30
2024
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,437
-6.35%
|
$82,488
$24.3 P/Share
|
|
Oct 30
2024
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,957
+5.51%
|
-
|
|
Oct 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,368
-5.97%
|
$56,832
$24.3 P/Share
|
|
Oct 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+7.26%
|
-
|